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Mode of induction 
of platelet‑derived extracellular 
vesicles is a critical determinant 
of their phenotype and function
P. M. Ferreira1, E. Bozbas1, S. D. Tannetta1, N. Alroqaiba1, R. Zhou1, J. T. B. Crawley2, 
J. M. Gibbins3, C. I. Jones3, J. Ahnström2 & P. Yaqoob1*
Platelet‑derived extracellular vesicles (PDEVs) are the most abundant amongst all types of EVs in 
the circulation. However, the mechanisms leading to PDEVs release, their role in coagulation and 
phenotypic composition are poorly understood. PDEVs from washed platelets were generated using 
different stimuli and were characterised using nanoparticle tracking analysis. Procoagulant properties 
were evaluated by fluorescence flow cytometry and calibrated automated thrombography. EVs 
from plasma were isolated and concentrated using a novel protocol involving a combination of size 
exclusion chromatography and differential centrifugation, which produces pure and concentrated 
EVs. Agonist stimulation enhanced PDEV release, but did not alter the average size of EVs compared 
to those produced by unstimulated platelets. Agonist stimulation led to lower negatively‑charged 
phospholipid externalization in PDEVs, which was reflected in the lower procoagulant activity 
compared to those generated without agonist stimulation. Circulating EVs did not have externalized 
negatively‑charged phospholipids. None of the 4 types of EVs presented tissue factor. The mechanism 
by which PDEV formation is induced is a critical determinant of its phenotype and function. 
Importantly, we have developed methods to obtain clean, concentrated and functional EVs derived 
from platelet‑free plasma and washed platelets, which can be used to provide novel insight into their 
biological functions.
Circulating extracellular vesicles (EVs) originate from a number of sources, including platelets, erythrocytes, 
leukocytes and endothelial  cells1. Recent data suggests their involvement in a range of physiological and patho-
physiological processes, including inflammation, cell communication, coagulation and  metastasis2,3. EVs are 
commonly classified into exosomes (30–150 nm), microvesicles (100–1000 nm; also referred to as microparticles 
or ectosomes), and apoptotic bodies (1000–3000 nm)4. However, definitive discrimination has not yet been 
established due to the overlapping sizes and lack of accurate methods for separation and characterization. Many 
studies therefore use the generic term, EVs, together with a description of the size range of the particles under 
 investigation5. The most abundant type of EVs in circulation are platelet-derived extracellular vesicles (PDEVs)6. 
Originally identified in platelet-free plasma, PDEVs were shown to be rich in negatively-charged phospholipids 
and demonstrated to support  coagulation7. Studies have shown PDEVs to be released upon platelet activation by 
agonists, hemodynamic stress, ageing and inflammatory  pathologies8 and while studied widely in vitro there is 
little understanding of the degree to which the PDEVs generated ex vivo are similar to those in the circulation, 
both in terms of composition and of functional properties.
Phospholipids in plasma membranes are organized in two layers, with phosphatidylcholine (PC) in the outer 
leaflet facing the circulation, and phosphatidylserine (PS) and phosphatidylethanolamine (PE) facing the inner 
leaflet. During the normal haemostatic response, platelets can become activated and PS and PE are relocated 
to the outer leaflet, creating a negatively-charged membrane surface which supports the formation of protein 
complexes that together form the coagulation cascade. This chain of enzymatic reactions leads to the generation 
of thrombin, followed by fibrin and ultimately, the formation of a stable platelet  plug9. Negatively-charged PDEVs 
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can serve as additional surfaces where coagulation cascade complexes can  assemble10. Clinical evidence suggests 
that PDEVs could protect from bleeding during idiopathic thrombocytopenic purpura, while their dramatic 
release could be related to neurological complications of thrombotic  origin11. Importantly, PDEVs have shown 
to be highly heterogenous in size and  composition12 and not all PDEVs externalize PS/PE13, but the mechanisms 
leading to their exposure and functional activity of these different populations are poorly understood.
The structural diversity and dimensions of PDEVs produced by quiescent vs agonist-stimulated platelets are 
 different14. However, whether vesicles produced by different stimuli also have distinctive functions, particularly 
procoagulant function, is not known. In the current study we have significantly advanced earlier observations by 
evaluating novel methods for PDEV generation and by demonstrating that agonist stimulation of platelets from 
healthy volunteers led to lower phospholipid externalization in the generated PDEVs. This was reflected in the 
lower procoagulant function of these PDEVs. In contrast, circulating EVs isolated from healthy volunteers did 
not have externalized negatively charged phospholipids and did not present tissue factor.
Methods
Subject recruitment and characteristics. Male and female subjects aged 18–60 years and free of diag-
nosed disease were recruited to provide blood samples. All procedures were conducted according to the prin-
ciples of the Declaration of Helsinki and approved by the School of Chemistry, Food and Pharmacy Research 
Ethics committee (project 15/17), on behalf of the University of Reading Ethics Committee. All subjects gave 
written informed consent before providing samples.
Blood collection and platelet isolation. Blood from fasted volunteers was obtained by venepuncture 
from the median cubital vein using a 19G butterfly needle. The first 5 ml of collected blood was discarded. The 
blood to be used in this study was drawn into a vacutainer containing tri-sodium citrate (3.2%; Greiner Bio-One, 
UK) and processed within 30 min. To obtain platelet free plasma (PFP), blood was centrifuged at 1500×g for 
15 min and the upper two thirds were collected and centrifuged again at 13,000×g for 2 min. The upper three 
quarters from each tube were collected and identified as PFP.
Blood was centrifuged at 175×g for 15 min to obtain platelet-rich plasma (PRP). Platelets were then iso-
lated by further centrifugation (1000×g, 10 min) in the presence of prostacyclin  (PGI2, 1 µg/ml; Sigma, UK). 
The resulting pellet was washed in modified Tyrode’s (MTH) buffer (containing 134 mM NaCl, 2.9 mM KCl, 
0.34 mM  Na2HPO4, 12 mM  NaHCO3 and 1 mM  MgCl2; pH 7.4) containing HEPES (20 mM; Sigma, UK) and 
re-suspended in an equal volume of MTH. Platelets were counted and adjusted to a final working concentration 
of 3 × 108 platelets/ml.
Purification and concentration of circulating EVs from PFP. Size exclusion chromatography (SEC), 
using ready made columns (qEV, Izon Science) was used for EV isolation from PFP. After equilibrating the col-
umn with 20 ml of 20 mM Tris–HCl pH 7.5, 0.15 M NaCl (TBS), 0.5 ml of PFP was layered on top and allowed to 
enter the column. The top reservoir was then filled with TBS and 0.5 ml fractions were collected. Protein content 
on fractions was measured with the Pierce BCA Protein Assay Kit (Thermo Scientific, Cat #23225). Fractions 
were numbered in order of collection and the EV-rich fractions free of plasma proteins (Fractions 7–10) were 
kept at 4 °C (Supplemental Fig. S1). This procedure was repeated 4 more times, so that EVs were isolated from 
2.5 ml of PFP from each volunteer. Altogether, 20 eV rich fractions were obtained for each volunteer, pooled 
and centrifuged at 15,000×g at 4 °C for 30 min. The supernatant was removed and the pellet rich in EVs was 
resuspended in a final volume of 0.4 ml. These were called PFP EVs.
Production of PDEVs from washed platelets and PRP. In the presence of 2 mM  CaCl2, washed plate-
lets were stimulated with either 30 µM thrombin receptor activator peptide (TRAP-6; Bachem, UK) or MTH 
(non-stimulated) and incubated at 37 °C for 2 h (Supplemental Fig. S2), as described  previously15. Platelets were 
then removed by two sequential centrifugations at 1200×g for 10 min. The supernatant, containing the EVs, was 
collected and centrifuged at 15,000×g for 30 min at 4 °C. The pellet containing EVs was stored at − 80 °C. These 
were called TRAP-6 PDEVs and Buffer PDEVs, respectively.
PRP was stimulated with TRAP-6 using the same protocol as described for washed platelets above. Thereafter, 
the stimulated PRP was centrifuged to generate PFP and EVs were isolated and concentrated using the methods 
outlined above. These generated vesicles were called PRP+ TRAP-6 EVs.
Calibrated automated thrombography. The procoagulant properties of the different EV prepara-
tions were assessed by calibrated automated thrombography (CAT) using a Fluoroskan Ascent FL plate reader 
(Thermo Labsystem) in combination with Thrombinoscope software (Synapse BV). For this purpose, a plasma 
pool from 13 healthy volunteers was prepared. The blood was collected in 10 mM sodium citrate and 18 µg of 
corn trypsin inhibitor (Enzyme Research Laboratories) per ml of blood and spun as described  previously16.
Thrombin generation was initiated in plasma by 16.6 mM  CaCl2 in the presence or absence of 1 or 4 pM 
tissue factor (TF; Dade Innovin) and/or 4 µM phospholipid vesicles. The amount of thrombin formed was 
monitored using 0.42 mM of Z-Gly-Gly-Arg-AMC (Bachem) and quantified against a “calibrator” sample with 
known amount of alpha2M-thrombin complex run in parallel with the other samples, according to standard 
procedures (Stago)17.
The EVs were quantified by absorption at 280 nm using an extinction coefficient (E1%, 1 cm) of 10 and were 
added to the reaction at 0–16 µg/ml.
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Phospholipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoserine 
(DOPS), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) (Avanti Polar Lipids) were mixed at a 
ratio of 60:20:20 and prepared by extrusion as described  previously16,18.
Antibody labelling. Extracellular vesicles were assessed for their ability to bind cell marker-specific mono-
clonal antibody anti CD41 conjugated to Phycoerythrin (PE) (BioCytex Cat# 5112-PE100T) to detect PDEVs, 
Annexin V conjugated to Allophycocyannin (APC) (ThermoFisher, Cat# BMS306APC-100), which binds exter-
nalized PS residues, and duramycin (DM) (Sigma, Cat# D3168), which was conjugated to Atto-488 dye (Ther-
moFisher, Cat # 710369) and specifically binds  PE19. Samples were double stained: 1–5 μl of each EV sample 
with both anti CD41 and Annexin V or DM was carried out for at least 30 min in the dark at room temperature, 
followed by dilution with Annexin V-binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM  CaCl2, pH 7.4).
Flow cytometric analysis. Firstly, the limits of detection of the flow cytometer (Canto II Flow Cytometer 
(BD Biosciences, UK)) and the EV gate were established using standard size calibration beads (Apogee Flow 
Systems, Hemel Hempstead, UK), comprised of 180 nm, 240 nm, 300 nm, 590 nm, 880 nm and 1300 nm silica 
beads and 110 nm and 500 nm green fluorescent latex beads, to determine the optimum side scatter (SSC) and 
forward scatter (FSC) voltages for EV detection: 540 and 500 respectively. The EV gate included all particles of 
size 240 nm–1 µm, in which the lower detection limit was set by 240 nm silica beads to exclude noise, while the 
upper detection limit was set just above 880 nm silica beads to exclude platelets, larger debris and contamina-
tions (Supplemental Fig. S3). Each sample was measured successively using different triggering signals. Firstly 
the SSC signal was used to trigger detection of EVs based on light scattering (Threshold 700) and to establish an 
optimum dilution, which was kept at around 300 events/second. After that, the instrument was switched to fluo-
rescence mode and the signal was triggered on the detector correspondent to the fluorophore of the antibody of 
interest: CD-41 PE (λex. = 496 nm, λem. = 578 nm; Voltage 470, Threshold 350), Annexin V APC (λex. = 650 nm, 
λem. = 660 nm; Voltage 642, Threshold 550) and Duramycin FITC (λex. = 490 nm, λem. = 525 nm; Voltage 642, 
Threshold 550). Fluorescence triggering provides higher sensitivity by removing interference from noise and 
particles that would be detectable using light scattering  triggering13. All chemicals were filtered using 100 nm 
syringe filters (Sartorius, UK) and 100 nm centrifugal devices (Sartorius, UK) and analysed for 1 min (10 µl) to 
assess the level of background particles that fell in the EV gate.
Events were collected for 1 min (10 µl) on the threshold corresponding to the labelled fluorophore at “Low” 
flow rate (10 µl/min). For anti CD41, sample incubation with its isotype control had lower fluorescence than 
the antibody on its own; therefore the background was set on the fluorescence produced by the antibody only.
EV positive events were calculated, by subtracting the number of events acquired from the antibody mix on 
each experimental day from the absolute count of positive events of the labelled sample (Supplemental Fig. S4). 
Ratios between phospholipid externalization (PS and PE) were calculated by dividing the number of positive 
events obtained on APC (PS) and FITC (PE) channels by the number of positive events obtained on the PE 
(CD41) channel. Data was captured using FACSDiva Software version 6.1.3 and analysed using FlowJo version 10.
Nanoparticle tracking analysis. Size distribution and concentration of EVs were analysed by Nanoparti-
cle Tracking Analysis (NTA) using a NanoSight NS300 instrument (Malvern Instruments). Samples were diluted 
in PBS to achieve a concentration of approximately 1–9 × 108 particles/ml and injected into the NanoSight sam-
ple chamber using a 1 ml syringe and syringe pump. Five 1-min videos were captured at camera level 13 and 
frame rate of 25 per second and analysed by Nano 3.2 software.
Statistical analysis. Statistical analyses were performed using GraphPad Prism software. Paired student’s 
T-test was performed for head-to-head comparisons. Non-linear fit models were generated for CAT concentra-
tion–response curves and extra sum-of-squares F test was used for comparison between curves. For all tests, 
p < 0.05 was considered statistically significant.
Results and discussion
In the current study, platelets were washed and PDEVs were generated in the presence or absence of TRAP-6 
stimulation, followed by isolation under the same conditions through differential centrifugation. The gener-
ated vesicles were initially characterised by number and size using NTA. TRAP-6 stimulation enhanced PDEV 
release (8.6 × 109 vs 4.2 × 109 vesicles/ml from buffer only (p = 0.01); Fig. 1A. In contrast, there was no difference 
in average size (TRAP-6 PDEVs = 190.3 nm vs Buffer PDEVs = 191.6 nm; Fig. 1B. These findings are in line with 
previous reports where it has been demonstrated that platelet thrombin receptor stimulation boosts formation 
of small PDEVs (50–100 nm)14, whilst the average size of the thrombin-stimulated platelet-derived EVs is not 
statistically different from EVs generated from unstimulated  platelets12 (Fig. 1).
The PDEV concentration steps performed, although done on a benchtop centrifuge, produce a sample which 
is 8.5 times more concentrated than its respective supernatant (Supplemental Fig. S5). This is imperative for the 
CAT assays where a sample needs to be over 100 µg/ml in protein concentration for adequate testing. The neat 
supernatant does not reach this concentration so we could not test its functional properties. Flow cytometry 
also would not be a reliable approach for characterisation given that the average size of the EVs present in the 
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To assess whether mode of platelet stimulation influences PS and PE exposure, the vesicles were characterised 
using flow cytometry. TRAP-6 stimulation led to lower PS and PE externalization compared to vesicles generated 
in the absence of agonist (Fig. 2A,B). This was also reflected in the lower procoagulant properties of TRAP-6 
stimulated PDEVs when investigated in CAT assays in the presence of TF (Fig. 2C,D).
In previous studies investigating the ability of PDEVs to support thrombin generation, it was shown that size 
altered their procoagulant properties where smaller vesicles (142 ± 12 nm) stimulated less thrombin generation 
than a larger population (173 ± 15 nm)4,20. The current study demonstrates that not only size is important for 
the negatively-charged phospholipid exposure profiles and procoagulant activity, but the stimuli that triggered 
PDEVs generation.
The majority of circulating EVs do not present PS on their outer  surface13 and these are mainly  PDEVs6. Puri-
fication methods of circulating EVs rely solely on differential centrifugation from PFP, leaving the final extract 
contaminated with plasma proteins and  immunocomplexes21. These can potentially interfere with functional 
assays and lead to underestimation of the EV concentration if determined by protein content. Counting EVs by 
flow cytometry or NTA would also lead to misinterpretation, since there is no valid general marker for EVs and 
NTA is unable to differentiate vesicles from protein aggregates.
As a result of these limitations, we have developed a novel purification method, which produced circulating 
EVs free of most plasma proteins and at a concentration that allows them to be employed in functional experi-
ments. EVs were isolated from plasma by SEC and subsequently concentrated through differential centrifugation. 
It has been shown previously that SEC removes 99% of soluble plasma proteins and > 95% of HDL from the purest 
fraction of  EVs22, without inducing aggregation of  EVs23 while retaining their integrity and biological  activity24. 
Only Fractions 7–10 were collected in order to avoid the presence of plasma proteins. As shown on Supplemental 
Fig. S1, plasma proteins start to increase substantially after Fraction 11. Even if a small plasma protein contami-
nation is unavoidable, these should remain in the supernatant after the final centrifugation step. The fact that 
PRP+ TRAP-6 EVs had a similar potency to TRAP-6 EVs on CAT (compare Fig. 2C, 3A) validates the novel EV 
SEC purification protocol from plasma since their concentration was determined by protein content, although 
generated via two different protocols. If there would be significant protein contamination on PRP+ TRAP-6 EVs 
these would have lower potency compared to TRAP-6 PDEVs.
To investigate how PDEVs functionally relate to circulating EVs in healthy volunteers, PRP was stimulated 
with TRAP-6, centrifuged to produce PFP, which was then subjected to SEC to purify the EVs. In parallel, another 
sample of PFP, from the same volunteer, was used to purify EVs present without any stimulation—representing 
the circulating EVs. The two types of EVs were isolated and quantified in exactly the same way. PDEVs isolated 
from ‘stimulated’ PRP supported thrombin generation in a dose-dependent manner, demonstrating that the 
agonist-stimulation of PRP followed by EV purification produced functional EVs (Fig. 3A). In contrast, circulat-
ing EVs (derived from unstimulated PFP) did not support thrombin generation at concentrations up to 16 µg/
ml (Fig. 3A). This was explained by the low levels of PS exposure detected on the outer layer of circulating EVs, 
which is essential for thrombin generation (Fig. 3B).
The presence of TF on circulating EVs and on PDEVs and its potential influence on their procoagulant 
function has been a matter of  debate4,25,26. To address this, the ability of EVs (10 µg/ml) to support thrombin 
Figure 1.  Platelet agonist stimulation facilitates the formation of EVs with no difference in average vesicle 
size according to NTA. (A) Head to head comparison of tracked vesicle concentration generated from either 
unstimulated (Buffer) platelets or platelets stimulated by the addition of TRAP-6. Vesicles generated from 
1 ml of 3 × 108 platelets in 1 ml of MTH buffer. Platelets were then removed and the supernatant injected on 
NTA. Two-tailed paired t-test, p = 0.001, n = 11. (B) Comparison of tracked vesicle average size. No significant 
difference was observed from both types of vesicles: Buffer PDEVs = 191.6 nm × TRAP-6 PDEVs = 190.3 nm. 
Results are presented as Mean ± SD, n = 8. Two-tailed paired t-test p = 0.663, n = 11.
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generation in the absence of TF, but in the presence of synthetic negatively-charged phospholipid membranes was 
evaluated. These results demonstrated a complete absence of thrombin generation in the absence of TF (Fig. 4). 
Conclusions
In summary, this study demonstrates that the mechanism by which PDEV formation is induced is a critical 
determinant of their phenotype, but not size. PDEVs derived via different mechanisms (i.e. from washed plate-
lets vs PFP and unstimulated vs stimulated) exhibited different procoagulant properties. Novel methods were 
developed to obtain clean, concentrated and functional EVs derived from both PFP and from washed platelets, 
which can be used to provide new insights into their biological composition and function. Further studies are 
necessary to determine the mechanisms by which platelets release different EV populations.
Figure 2.  Platelet-derived EVs generated without agonist stimulation are more procoagulant than 
those generated by of TRAP-6. (A,B) Relationship of phosphatidylserine (PS) positive events (A) and 
phosphatidylethanolamine (PE) positive events (B) divided by CD41 positive events for unstimulated and 
TRAP-6 stimulated PDEVs. Events were captured on the fluorescence mode on the PE channel (CD41+), APC 
channel (PS+) and on the FITC channel (PE +). n = 6–7. Two-tailed paired t-test (A) p = 0.026, (B) p = 0.088. 
(C,D) Procoagulant properties of 0–16 or 0–13 µg/ml PDEVs were assessed using CAT in the presence of 
1 pM (C) or 4 pM (D) TF, respectively. Dose–response curves representing peak thrombin generation are 
plotted against PDEVs concentration. Results are presented as mean ± SEM, n ≥ 3. A non-linear fit regression (4 
parameters) was performed on (C,D) and the best-fit values were compared. (C) p = 0.001, (D) p = 0.293.
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Figure 3.  Circulating extracellular vesicles (EVs) do not externalize PS and consequently do not support 
thrombin generation. (A) The procoagulant properties of 0–16 µg/ml circulating EVs (PFP) or stimulated 
PDEVs+ circulating EVs (PRP) were assessed using CAT in the presence of 1 pM TF. Dose–response curves 
representing peak thrombin generation are plotted against vesicle concentration. Results presented as 
Mean ± SD, n = 4. (B) Phosphatidylserine exposure was determined by Annexin V binding to PFP and PRP EVs 
and quantified through fluorescence flow cytometry. Due to low Annexin V binding, PFP EVs do not carry 
negatively charged phospholipids and consequently cannot support thrombin generation on its surface. Results 
presented as Mean ± SD, n = 8.
Figure 4.  Circulating and PDEVs do not express TF. To assess whether EVs from different sources could 
stimulate thrombin generation in the absence of TF, 10 µg/ml of all types of EVs studied here were added to 
normal plasma, in the presence and absence of synthetic phospholipid membranes (4 µM). The peak thrombin 
generation was compared to that generated by normal plasma alone in the presence of 4 µM phospholipids and 
1 pM TF. Results presented as Mean ± SD, n ≥ 3.
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